Top expert reveals shocking first sign of type of dementia that hits in your 30s - 'patients think it's normal'
While dementia is most often associated with the elderly, it can affect people of all ages.
One type in particular, frontotemporal dementia (FTD), is most often diagnosed in men and women aged between 45 and 65, but there have been confirmed cases of it in people decades younger.
The first signs of FTD are often related to changes in behaviour; people can become rude or violent, struggle with their words or communication, or start to behave in impulsive or risky ways.
But as these behaviours are often mistaken for another health condition, or simply written off as an unpleasant blip in someone's usually calm and collected demeanour, people can end up very, very unwell before they get the help they need.
Paul Little, CEO of Vesper Bio, a biotech firm working to improve the lives of people diagnosed with FTD, said that a misdiagnosis can have serious repercussions.
Speaking to the FT, he explained: 'There are patients as young as 29 that's not uncommon, who get frontotemporal dementia (FTD).
'Often times it's misdiagnosed as bipolar disorder or some form of midlife crisis, because in some cases, there's a behavioural component.
View this post on Instagram
A post shared by FT Partner Content (@ftpartnercontent)
'The patient may start drinking heavily, may get into trouble with the police and end up in the wrong form of help.'
He added that there is no cure for FTD, and that tragically it is never just the person who is diagnosed who suffers—it has massive ramifications which ripple outwards, destroying the lives and dreams of everyone close to them.
Mr Little continued: 'It's invariably fatal when you get the disease, it's catastrophic for families, because you will see changes in behaviour and changes in language that mean that the patient themselves is unable to work.
'It means that caregivers also have to give up jobs, and these are the most fruitful, best parts of life for earning money and building families.'
Figures released by the Alzheimer's Society reveal that there are around 70,800 people in the UK living with early-onset, or young-onset, dementia, which is defined as when symptoms start before the age of 65.
The causes of dementia in younger people are essentially the same as for older patients.
In the case of Alzheimer's, proteins build up in the brain, forming plaques and tangles.
With vascular dementia, this is caused by problems with the blood supply to the brain, and might be the result of heart disease.
FTD is a rarer form of the condition, and affects 16,000 people in the UK.
It leads to a loss of cells in the front and side of the brain which are the areas that control behaviour, hence why it might cause changes to how people interact with others, or care for themselves.
Although it can progress slowly, survival time after an FTD diagnosis is between just two and 12 years.
Concerns have been raised about a rise in cases of young-onset dementia in the UK.
A study of GP practice records in England in 2022 revealed an alarming 69 per cent increase since 2014 (from 28,800 cases).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
28 minutes ago
- Reuters
Viking's weight-loss pill data disappoints, shares sink
Aug 19 (Reuters) - Viking Therapeutics (VKTX.O), opens new tab said Tuesday its experimental weight-loss pill helped patients lose 12.2% of their body weight in a mid-stage trial, missing Wall Street's top-end expectations of 15% and sending its shares plummeting by 41%. In the 280-person study of obese and overweight adults, those who received the highest 120-milligram dose of Viking's drug, VK2735, shed 12.2% of their body weight on average over 13 weeks versus 10.9% for those who received a placebo. However, about 20% of patients on VK2735 dropped out of the study due to adverse effects, primarily gastrointestinal issues such as vomiting and nausea, compared to 13% in the placebo group. The company will consider increasing it every four weeks for future studies, rather than every two weeks, to help control the side effects, Viking CEO Brian Lian said. Oral weight-loss drugs are expected to widen access for patients averse to injections, helping their makers tap into a projected $150 billion market currently dominated by Novo Nordisk's ( opens new tab Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound. But so far, oral pills have failed to outperform the injectables in the tight race for these medicines. Analysts expected Viking's drug to help lower body weight by 10% to 15%, following an 8.2% average reduction in an early-stage trial. J.P. Morgan analyst Hardik Parikh said the drug's profile did not measure up to earlier trials, but said side effects might be manageable with dose adjustments, particularly given the high discontinuation rate in the placebo group. Shares of Viking had gained 4.6% this year till Monday's close due to optimism over the obesity pill. In early August, Lilly's experimental daily pill, orforglipron, showed a 12.4% weight loss in a late-stage study over 72 weeks. The news wiped off more than $100 billion from the company's market value on the day. Separately, Novo's oral semaglutide has shown a weight-loss of 15% over 68 weeks. Both drugmakers expect to launch their oral drugs by next year.
Reuters
28 minutes ago
- Reuters
US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder
Aug 19 (Reuters) - The U.S. Food and Drug Administration has denied approval for PTC Therapeutics' (PTCT.O), opens new tab oral medication for a rare genetic disorder with limited treatment options, the company said on Tuesday. In its so-called Complete Response Letter, the FDA said the data did not provide substantial efficacy evidence for the drug, vatiquinone, in treating Friedreich's ataxia and that a separate study was needed before resubmitting the application. At least three analysts said the regulator's rejection was not surprising and that expectations had been low heading into the decision. PTC's shares reversed premarket losses to rise more than 8% in morning trading. The FDA approved Sephience - PTC's oral therapy for a rare metabolic disorder called phenylketonuria - last month, potentially countering revenue declines due to regulatory scrutiny and competition from cheaper rivals for its top-selling muscular disorder therapies, Translarna and Emflaza. "We see today's CRL as a clearing event since investors can now turn their focus to the Sephience launch," analysts said in a client note. The company said it planned to meet with FDA officials to discuss potential next steps. "We are of course disappointed by the FDA's decision to not approve vatiquinone," CEO Matthew Klein said, adding that the data till date demonstrated that the drug could be safe and effective for children and adults living with the disorder. Friedreich's ataxia is a rare genetic disorder that causes progressive damage to the nervous system, often leading to difficulty in walking, speech problems and heart complications. The disease tends to develop in children and teenagers and gradually worsens over time. Vatiquinonedid not meet its main goal, opens new tab of significantly reducing disease progression in a key late-stage trial that was part of the company's marketing application. Currently, Biogen's (BIIB.O), opens new tab Skyclarys remains the only FDA-approved treatment for Friedreich's ataxia.
The Guardian
42 minutes ago
- The Guardian
Action needed on plastic additives linked to sperm decline, experts warn
Action must be taken to curb the use of plastic additives linked to plummeting sperm counts, a leading reproductive scientist has warned, as splits over chemical regulation contributed to the collapse of a crucial treaty on plastic pollution. Across the world, sperm counts have been declining at a rate of about 1% a year for the past 50 years, and human fertility has been diminishing at a similar rate, studies have shown. Increasing levels of obesity, sedentary lifestyles and ageing populations have all been held up as possible causes. But according to Dr Shanna Swan, professor of environmental medicine and public health at the Icahn School of Medicine at Mount Sinai in New York City, environmental factors play the most significant role. Swan said the decline was 'largely, but not entirely due to toxins in the environment that have the ability to interfere with steroid hormones'. In 2017, Swan and her colleagues published a meta-analysis showing a decline in sperm counts of almost 60% among men in North America, Europe and Australia between 1973 and 2011. In 2023, they repeated the research, extending the study to 2018 and including previously unavailable data from Africa, Asia and South America, and made even more shocking findings. 'We separated the countries into western and non-western for analytic purposes, and in both we found a significant decline,' Swan said. 'And the other thing that we found, which was at least as alarming, was that if you looked at all of the studies going back to 1973 you see a 1% per year decline. But if you look at studies published after 2000, you see an over 2% decline. 'So the rate of decline had increased, and had increased significantly in recent years.' Swan's warning comes amid rising alarm at the impact of chemical toxicity on human and environmental health. Two weeks ago, a report published by Deep Science Ventures, a business focused on environmental solutions, which was reviewed by Swan, warned that chemical pollution was 'a threat … of a similar order as climate change', but received far less attention. The decline in sperm rates since about 1950 stands in an inverse relationship to the explosion in the use of plastics. Swan points out that there are now well-established links between common additives to plastics and falling sperm counts. 'Phthalates are chemicals that are put into plastic to give it flexibility and make it soft and flexible,' Swan said. 'So anytime you pick up a soft water bottle or tubing, like medical tubing, or a food container that's soft, you're going to be touching phthalates. 'Then, on the other side, the evil twin of phthalates are the bisphenols. While phthalates make plastic soft and flexible, bisphenols make it hard and inflexible. And phthalates lower testosterone and the bisphenols increase oestrogen.' The effects of these and other endocrine-disrupting chemicals were particularly profound on foetuses and embryos developing in the womb, Swan said. She had previously carried out research into the effects of phthalates on unborn male babies, finding that exposure at a critical point in gestation could lead to subtle deformities in sexual development. Sign up to Down to Earth The planet's most important stories. Get all the week's environment news - the good, the bad and the essential after newsletter promotion The adverse effects of phthalates in the womb, known as 'phthalate syndrome', included smaller penises, a shorter distance between the genitals and anus, and – once children reached sexual maturity – lowered sperm counts, Swan said. 'We showed the link between the exposure and fertility,' she said. 'And when you see that total sperm count going down worldwide, what I believe is you're seeing an important effect of early exposure to these chemicals.' Swan would not be drawn into commenting on the talks, which were under way as she spoke, in Geneva for a comprehensive treaty to end the plastic pollution crisis. But she said action needed to be taken on the use of plastic additives, with an urgent need for safer replacements. 'In the meantime, yes people can be careful,' she said. 'They can reuse materials. They should try to look at what they use in their takeout containers and carry little glass bottles around to get their drinks. It's very important. But it's not solving a bigger problem, which is how do we make these things that we have become dependent on in a safer way?' Signs of a solution are not promising. Last week, after nearly two weeks of talks, negotiators left Geneva on Friday having failed to reach an agreement, after oil- and gas-producing nations objected to calls for limits to production and curbs on chemicals. Almost 100 nations had signed a declaration calling for a 'legally binding obligation to phase out those most harmful plastic products and chemicals of concern'. But both texts drafted by Luis Vayas Valdivieso, the chair of the negotiating committee, omitted any reference to controls on chemicals.
